112418-19-6

Basic information

• Product Name: D-Serine, N-[(1,1-dimethylethoxy)carbonyl]-O-[(1,1-dimethylethyl)dimethylsilyl]-, methyl ester
• CAS NO: 112418-19-6
• Molecular Formula: C15H31NO5Si
• Molecular Weight: 333.5
• Mol File: 112418-19-6.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: D-Serine, N-[(1,1-dimethylethoxy)carbonyl]-O-[(1,1-dimethylethyl)dimethylsilyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: D-Serine, N-[(1,1-dimethylethoxy)carbonyl]-O-[(1,1-dimethylethyl)dimethylsilyl]-, methyl ester(112418-19-6)
• EPA Substance Registry System: D-Serine, N-[(1,1-dimethylethoxy)carbonyl]-O-[(1,1-dimethylethyl)dimethylsilyl]-, methyl ester(112418-19-6)

Safety Data

• Hazardous Substances Data: 112418-19-6(Hazardous Substances Data)

Upstream product

• 95715-85-8 2-(tert-butoxycarbonylamino)-3-hydroxypropionic acid methyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 218766-12-2 (4R,5R)-4-[(tert-butyldimethylsilyloxy)methyl]-5-phenyloxazolidin-2-one 
• 753487-55-7 (2S,3R)-N-(tert-butyloxycarbonyl)-3-methoxyphenylalanine 
• 90242-16-3 (5S)-5-<(tert-butoxycarbonyl)amino>cyclohexadienecarboxylic acid 
• 950690-19-4 ethyl (S)-5-((tert-butoxycarbonyl)amino)cyclohexa-1,3-diene-1-carboxylate 
• 185692-85-7 tert-butyl (S)-1-(tert-butyldimethylsilyloxy)-3-hydroxypropan-2-yl carbamate 
• 372119-42-1 (4R,5R)-4-tert-butyldimethylsilyloxymethyl-2-phenyl-5-(2-propenyl)-2-oxazoline 
• 328086-54-0 (2E,4S)-4-(tert-butoxycarbonylamino)-5-[(3'S)-2'-oxo-3'-pyrrolidinyl]-2-pentenoic acid ethyl ester 
• 249736-45-6 [2-hydroxy-1S-(2-oxopyrrolidin-3S-ylmethyl)ethyl]carbamic acid tert-butyl ester 

Relevant articles and documents

Morita-Baylis-Hillman approach toward formal total synthesis of tamiflu and total synthesis of gabaculine

A Morita-Baylis-Hillman reaction mediated approach to the formal total synthesis of oseltamivir and the total synthesis of gabaculine is described. This strategy involves the enantiocontrolled preparation of Corey's intermediate in 22 % yield, which is pr

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acc

Structure-activity relationships of lysophosphatidylserine analogs as agonists of G-protein-coupled receptors GPR34, P2Y10, and GPR174

Lysophosphatidylserine (LysoPS) is an endogenous lipid mediator generated by hydrolysis of membrane phospholipid phosphatidylserine. Recent ligand screening of orphan G-protein-coupled receptors (GPCRs) identified two LysoPS-specific human GPCRs, namely, P2Y10 (LPS2) and GPR174 (LPS3), which, together with previously reported GPR34 (LPS1), comprise a LysoPS receptor family. Herein, we examined the structure-activity relationships of a series of synthetic LysoPS analogues toward these recently deorphanized LysoPS receptors, based on the idea that LysoPS can be regarded as consisting of distinct modules (fatty acid, glycerol, and l-serine) connected by phosphodiester and ester linkages. Starting from the endogenous ligand (1-oleoyl-LysoPS, 1), we optimized the structure of each module and the ester linkage. Accordingly, we identified some structural requirements of each module for potency and for receptor subtype selectivity. Further assembly of individually structure-optimized modules yielded a series of potent and LysoPS receptor subtype-selective agonists, particularly for P2Y10 and GPR174.